Skip to content
zameds

Nizatidine

Schedule 2 to 4, conditions apply
Loading the molecular structure
C12H21N5O2S2331.50 g/mol

1-N'-[2-[[2-[(Dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine

Drag to rotate. Structure from PubChem CID 4513.

Background

Loading...
Loading Wikipedia summary

Listing

Schedules
Schedule 2 to 4, conditions apply
Source
Consolidated Schedules 06 July 2026

Registered medicines

The ingredient index links no registered medicine to Nizatidine (register of 13 September 2026).

Counted through the register's ingredient index, which does not reach every record.

Regulatory status

Where S2 to S4 sits on the scale

Depends on which listing applies

At the least restrictive, Schedule 2: a pharmacist can sell it directly, without a prescription. At the most restrictive, Schedule 4: prescription-only medicine. The listings below say which applies to which form, strength or pack size.

Schedule S2 to S4, as the Consolidated Schedules list it.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Nizatidine

  • S4: Nizatidine

    • except when intended for oral administration for short-term symptomatic relief of heartburn and hyperacidity, where the maximum dose is 150 milligrams, the maximum daily dose is 300 milligrams and the maximum treatment period is two weeks. (S2)

    Consolidated Schedules 06 July 2026, lines 7313 to 7315

  • S2: Nizatidine

    • when administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to -
    • when a maximum dose of 150 milligrams;
    • when a maximum daily dose of 300 milligrams;
    • when a maximum treatment period of two weeks. (S4)

    Consolidated Schedules 06 July 2026, lines 2417 to 2423

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Research articles

Loading...
Loading PubMed articles